Duvalgagene otiparvovec

替哌度伐基

Report date: 2026/01/22 17:22:36

Base Information

Drug NameDuvalgagene otiparvovec
Drug Alias Name4D-310
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAV2 vector
Mechanisms of ActionGene transferenceα-Galactosidase replacements
Targetsα-Galactosidase
Therapy Area/IndicationsFabry Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesTaiwanAustralia
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator Companies4d Molecular Therapeutics Inc
China Registration ClassN/A

Develop Information

Active Companies4d Molecular Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsFabry Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A